Douglas L. Arnold - Concepedia

Author

Douglas L. Arnold

Montreal Neurological Institute and Hospital ORCID

Also Known As

A D Schwope, Amit Bar-Or, Arnold L. Douglas, Arnold, D, Arnold, DL, Arnold, Douglas, Arnold, Douglas L, Arnold, Douglas L., B. Kundu, CARE-MS II Investigators

1.1K

Publications

51.7K

Citations

111

H-Index

305

Concepts

All Affiliations

Montreal Neurological Institute and Hospital McGill University NeuroRx Research (Canada)University of Pennsylvania University of Toronto

About

Douglas L. Arnold is an author at Montreal Neurological Institute and Hospital specializing in medicine, neurology, and multiple sclerosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	67	176	17.7K
2	Health Sciences	28	39	4.7K
3	Engineering	23	32	2.5K
4	Education	2	2	44
5	Management	1	1	29

Douglas L. Arnold

420

Publications

45.6K

Citations

104

H-Index

Page 1

	Year	Citations
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold, New England Journal of Medicine	2008	2.4K
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni, New England Journal of Medicine	2016	1.9K
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos, New England Journal of Medicine	2016	1.8K
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis Ralf Gold, Ludwig Kappos, Douglas L. Arnold, New England Journal of Medicine	2012	1.7K
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold, The Lancet RheumatologyRelapsing-remitting Multiple SclerosisImmunologyClinical TrialsTreatment Option	2012	1.2K
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Alasdair Coles, Cary Twyman, Douglas L. Arnold, The Lancet ImmunologyClinical TrialsNeurological ProgressDisease-modifying TherapyMultiple Sclerosis	2012	1.2K
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials Ludwig Kappos, Jerry S. Wolinsky, Gavin Giovannoni, JAMA Neurology	2020	562
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy Mark C. Preul, Zografos Caramanos, D. Louis Collins, Nature Medicine EngineeringPet-mriDiagnosisNoninvasive DiagnosisGlioma	1996	528
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial Amit Bar‐Or, Peter A. Calabresi, Douglas L. Arnold, Annals of Neurology	2008	524

Page 1